Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients. / Laursen, Adam Høgsbro; Elming, Marie Bayer; Ripa, Rasmus Sejersten; Hasbak, Philip; Kjær, Andreas; Køber, Lars; Marott, Jacob Louis; Thune, Jens Jakob; Hutchings, Martin.

In: Journal of Nuclear Cardiology, Vol. 27, No. 5, 2020, p. 1698-1707.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Laursen, AH, Elming, MB, Ripa, RS, Hasbak, P, Kjær, A, Køber, L, Marott, JL, Thune, JJ & Hutchings, M 2020, 'Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients', Journal of Nuclear Cardiology, vol. 27, no. 5, pp. 1698-1707. https://doi.org/10.1007/s12350-018-1458-6

APA

Laursen, A. H., Elming, M. B., Ripa, R. S., Hasbak, P., Kjær, A., Køber, L., Marott, J. L., Thune, J. J., & Hutchings, M. (2020). Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients. Journal of Nuclear Cardiology, 27(5), 1698-1707. https://doi.org/10.1007/s12350-018-1458-6

Vancouver

Laursen AH, Elming MB, Ripa RS, Hasbak P, Kjær A, Køber L et al. Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients. Journal of Nuclear Cardiology. 2020;27(5):1698-1707. https://doi.org/10.1007/s12350-018-1458-6

Author

Laursen, Adam Høgsbro ; Elming, Marie Bayer ; Ripa, Rasmus Sejersten ; Hasbak, Philip ; Kjær, Andreas ; Køber, Lars ; Marott, Jacob Louis ; Thune, Jens Jakob ; Hutchings, Martin. / Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients. In: Journal of Nuclear Cardiology. 2020 ; Vol. 27, No. 5. pp. 1698-1707.

Bibtex

@article{ae82cabc4a254bd28ba7e0ccd87bf0cc,
title = "Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients",
abstract = "BACKGROUND: Doxorubicin is a cornerstone in lymphoma treatment, but is limited by dose-dependent cardiotoxicity. Rubidium-82 positron emission tomography (82Rb PET) assesses coronary microvascular function through absolute quantification of myocardial perfusion and myocardial perfusion reserve (MPR). Doxorubicin-induced microvascular injury represents a potential early marker of cardiotoxicity.METHODS AND RESULTS: We included 70 lymphoma patients scheduled for doxorubicin-based treatment. Cardiotoxicity was evaluated with 82Rb PET myocardial perfusion imaging during rest and adenosine stress before chemotherapy and shortly after the first doxorubicin exposure. Patients with a MPR decline > 20% were defined as having a low threshold for cardiotoxicity. In the 54 patients with complete data sets, MPR was significantly lower after the initial doxorubicin exposure (2.69 vs 2.51, P = .03). We registered a non-significant decline in stress perfusion (3.18 vs 3.02 ml/g/min, P = .08), but no change in resting myocardial perfusion. There were 13 patients with a low cardiotoxic threshold. These patients had a significantly higher age, but were otherwise similar to the remaining part of the study population.CONCLUSION: Decreases in MPR after initial doxorubicin exposure in lymphoma patients may represent an early marker of doxorubicin-induced cardiotoxicity. The prognostic value of acute doxorubicin-induced changes in MPR remains to be investigated.",
author = "Laursen, {Adam H{\o}gsbro} and Elming, {Marie Bayer} and Ripa, {Rasmus Sejersten} and Philip Hasbak and Andreas Kj{\ae}r and Lars K{\o}ber and Marott, {Jacob Louis} and Thune, {Jens Jakob} and Martin Hutchings",
year = "2020",
doi = "10.1007/s12350-018-1458-6",
language = "English",
volume = "27",
pages = "1698--1707",
journal = "Journal of Nuclear Cardiology",
issn = "1071-3581",
publisher = "Springer",
number = "5",

}

RIS

TY - JOUR

T1 - Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients

AU - Laursen, Adam Høgsbro

AU - Elming, Marie Bayer

AU - Ripa, Rasmus Sejersten

AU - Hasbak, Philip

AU - Kjær, Andreas

AU - Køber, Lars

AU - Marott, Jacob Louis

AU - Thune, Jens Jakob

AU - Hutchings, Martin

PY - 2020

Y1 - 2020

N2 - BACKGROUND: Doxorubicin is a cornerstone in lymphoma treatment, but is limited by dose-dependent cardiotoxicity. Rubidium-82 positron emission tomography (82Rb PET) assesses coronary microvascular function through absolute quantification of myocardial perfusion and myocardial perfusion reserve (MPR). Doxorubicin-induced microvascular injury represents a potential early marker of cardiotoxicity.METHODS AND RESULTS: We included 70 lymphoma patients scheduled for doxorubicin-based treatment. Cardiotoxicity was evaluated with 82Rb PET myocardial perfusion imaging during rest and adenosine stress before chemotherapy and shortly after the first doxorubicin exposure. Patients with a MPR decline > 20% were defined as having a low threshold for cardiotoxicity. In the 54 patients with complete data sets, MPR was significantly lower after the initial doxorubicin exposure (2.69 vs 2.51, P = .03). We registered a non-significant decline in stress perfusion (3.18 vs 3.02 ml/g/min, P = .08), but no change in resting myocardial perfusion. There were 13 patients with a low cardiotoxic threshold. These patients had a significantly higher age, but were otherwise similar to the remaining part of the study population.CONCLUSION: Decreases in MPR after initial doxorubicin exposure in lymphoma patients may represent an early marker of doxorubicin-induced cardiotoxicity. The prognostic value of acute doxorubicin-induced changes in MPR remains to be investigated.

AB - BACKGROUND: Doxorubicin is a cornerstone in lymphoma treatment, but is limited by dose-dependent cardiotoxicity. Rubidium-82 positron emission tomography (82Rb PET) assesses coronary microvascular function through absolute quantification of myocardial perfusion and myocardial perfusion reserve (MPR). Doxorubicin-induced microvascular injury represents a potential early marker of cardiotoxicity.METHODS AND RESULTS: We included 70 lymphoma patients scheduled for doxorubicin-based treatment. Cardiotoxicity was evaluated with 82Rb PET myocardial perfusion imaging during rest and adenosine stress before chemotherapy and shortly after the first doxorubicin exposure. Patients with a MPR decline > 20% were defined as having a low threshold for cardiotoxicity. In the 54 patients with complete data sets, MPR was significantly lower after the initial doxorubicin exposure (2.69 vs 2.51, P = .03). We registered a non-significant decline in stress perfusion (3.18 vs 3.02 ml/g/min, P = .08), but no change in resting myocardial perfusion. There were 13 patients with a low cardiotoxic threshold. These patients had a significantly higher age, but were otherwise similar to the remaining part of the study population.CONCLUSION: Decreases in MPR after initial doxorubicin exposure in lymphoma patients may represent an early marker of doxorubicin-induced cardiotoxicity. The prognostic value of acute doxorubicin-induced changes in MPR remains to be investigated.

U2 - 10.1007/s12350-018-1458-6

DO - 10.1007/s12350-018-1458-6

M3 - Journal article

C2 - 30298372

VL - 27

SP - 1698

EP - 1707

JO - Journal of Nuclear Cardiology

JF - Journal of Nuclear Cardiology

SN - 1071-3581

IS - 5

ER -

ID: 235913945